Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming ...

It's been a mediocre week for Alvotech ( NASDAQ:ALVO ) shareholders, with the stock dropping 17% to US$9.55 in the ...

Learn more about whether Alvotech or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which ...

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...

Alvotech (NASDAQ:ALVOW – Get Free Report) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 6,000 shares, a decline of 36.2% from ...

Northland Securities analyst Carl Byrnes maintained a Buy rating on Alvotech (ALVO – Research Report) today and set a price target of $28.00.

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

Good day and thank you for standing by. Welcome to the Alvotech Q4 2024 earnings call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a ...

Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...